New England Journal of Medicine· 2014Q1· Clinical trial
Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism
- 1,652citations
- Q1SCImago
- 2014year
Short summary
In intermediate-risk pulmonary embolism patients, tenecteplase plus heparin significantly reduced death or hemodynamic decompensation by 7 days (2.6% vs. 5.6%) compared to placebo, but increased major hemorrhage and stroke risk.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Internal Medicine
Internal MedicineMedicine